Table 1 NHERF1 in ependymal tumors and in other tumors considered in the differential diagnosis
From: NHERF1/EBP50 is an organizer of polarity structures and a diagnostic marker in ependymoma
Diagnosis | Patients | Site | NHERF1 microlumen positivity | ||||
|---|---|---|---|---|---|---|---|
| Â | No. cases gender | Mean age (range) | Â | Diffuse | Focal | Total/Site | Total |
Ependymoma | 341 | 44.6 (121-74) | ST: 51 | 5 (100%) | Â | 5 (100%) | 34 (100%) |
20M, 14F | PF: 8 | 8 (100%) | Â | 8 (100%) | |||
| Â | Â | Â | SC:21 | 18 (85%) | 32 (15%) | 21 (100%) | |
Adult Anaplastic ependymoma | 9 | 33 (23–49) | ST: 7 | 2 (28%) | 2 (28%) | 4 (57%) | 6 (67%) |
5M, 4F | PF: 1 | 1 (100%) | 0 | 1 (100%) | |||
| Â | Â | Â | SC: 1 | 0 | 1 (100%) | 1 (100%) | |
Pediatric Anaplastic ependymoma | 5 4F, 1M | 11.8 (6–17) | ST: 3 | 2 (67%) | 1 (33%) | 3 (100%) | 5 (100%) |
PF: 2 | 2 (100%) | 0 | 2 (100%) | ||||
Subependymoma | 6 4M, 2F | 60.5 (40–68) | ST: 5 PF: 1 | 5 (100%) 1 (100%) | 0 0 | 5 (100%) 1 (100%) | 6 (100%) |
Mixopapillary ependymoma | 5 3F, 2M | 45.6 (34–65) | SC: 5 | 0 | 3 (60%) | 3 (60%) | 33 (60%) |
Glioblastoma | 151 7M, 8F | 54.2 (121-76) | ST: 13 PF: 21 | 0 0 | 3 (23%) 0 | 3 (23%) 0 | 3 (20%) |
AT/RT | 2 2F | 0.75 (0.4-1.1) | PF: 2 | 0 | 0 | 0 | 0% |
Medulloblastoma | 6 5M, 1F | 24 (8–63) | PF: 6 | 0 | 0 | 0 | 0% |
Diffuse gliomas4 | 22 16M, 6F | 46.5 (27–78) | ST: 22 | 0 | 0 | 0 | 0% |
Pilocytic astroc. | 4 3M, 1F | 31.5 (18,61) | ST:1 PF: 2 SC: 1 | 0 | 0 | 0 | 0% |
Schwannoma | 5 3M, 2F | 46 (29–56) | PF: 4 SC: 1 | 0 | 0 | 0 | 0% |